Work

Personalized medicine approaches in cystic fibrosis related pancreatitis.

Year: 2022

Type: article

Abstract: . The Food and Drug Administration (FDA)-approved drug ivacaftor, a CFTR potentiator, was identified to robustly improve CFTR function in the context of this novel mutation. Herein, we describe a personalized medicine approach consisting of performing drug testing on individual patient derived organoids that has potential to guide management of patients with novel CFTR genetic mutations. Identified effective medical therapeutics using this approach may avoid irreversible surgical treatments such as total pancreatectomy with islet autotransplantation in the future.

Source: PubMed Central

Authors: Kyu Shik Mun, Jaimie D Nathan, Anil G Jegga, Kathryn A Wikenheiser-Brokamp, Maisam Abu-El-Haija, Anjaparavanda P Naren

Institutions: Cedars-Sinai Medical Center, Nationwide Children's Hospital, The Ohio State University Wexner Medical Center, Cincinnati Children's Hospital Medical Center, University of Cincinnati

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: Inhibition of an Apical cAMP/cGMP Transporter (MRP4) in the Gut Induces Diarrhea, Personalized Cystic Fibrosis Therapy and Research Center

OpenAlex ID: W4309413375

FWCI:

Cites: 24

Cited by:

Related to: 10